BC Extra | Jun 7, 2019
Clinical News

June 7 Clinical Quick Takes: Takeda discontinues Ninlaro for amyloidosis; plus La Jolla, Innovent and Atara

Takeda discontinues amyloidosis trial  Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) discontinued the Phase III TOURMALINE-AL1 trial to treat relapsed or refractory systemic amyloid light-chain (AL) amyloidosis after Ninlaro ixazomib plus dexamethasone missed the first of...
BC Week In Review | Apr 7, 2014
Company News

Eisai, Otsuka Pharmaceutical deal

Otsuka acquired from Eisai full rights to Dacogen decitabine in the U.S., Canada and Japan and now owns full worldwide rights to the cancer drug outside of Mexico, where Eisai retained rights. In 2008, Eisai...
Items per page:
1 - 2 of 2